Icon

ORSERDU (NDA217639)- (EQ 86MG BASE,EQ 345MG BASE)

ELACESTRANT HYDROCHLORIDE STEMLINE THERAP
EQ 86MG BASE,EQ 345MG BASE
No No
2038-Jan-05 2028-Jan-27
None None
None No
ORSERDU is an estrogen receptor antagonist indicated for: • treatment of postmenopausal women or adult men, with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
0 0 0
Total Other Developers 1
Drugs with Suitability No
EQ 86MG BASE ** ** - - -
EQ 345MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.